Abstract:Abstract Background Clozapine has remarkable efficacy on both negative and cognitive symptoms of schizophrenia due to its slight activation of NMDA receptor. In fact, much evidence to the contrary. NMDAR is a complex containing specific binding sites, which are regulated to improve negative symptoms and cognitive deficits associated with individuals affected by schizophrenia. PQQ is a powerful neuroprotectant that specifically binds with NMDA receptors in the brain to produce beneficial physiological and cognitive outcomes. The aim of this study was to enhance NMDAR function and improve cognitive ability in schizophrenia by PQQ combined with clozapine. Methods Rats were divided into four groups ( n = 5) including control (saline), model (MK-801, 0.5 mg·kg − 1 ·d − 1 ), atypical antipsychotic (MK-801 (0.5 mg·kg − 1 ·d − 1 ) + Clozapine (1.0 mg·kg − 1 ·d − 1 ), and co-agonist NMDA receptor (MK-801 (0.5 mg·kg − 1 ·d − 1 ) + Clozapine (0.5 mg·kg − 1 ·d − 1 ) + PQQ (1.0 μg·kg − 1 ·d − 1 ) group. Each group of rats was injected subcutaneously every day for 6 weeks. Behavior test, including stereotyped behavior, locomotor hyperactivity, learning and memory, was performed. The Western blot assay was performed to analyze the expression of GSK-3β, Akt, NMDAR1, and MGLUR in rat hippocampus. Results Results indicated that clozapine and PQQ combination therapy can improve MK801-induced schizophrenia behavior including stereotyped behavior, locomotor hyperactivity and cognitive impairment. Furthermore, we found that modulating NMDA receptors could ameliorate the memory impairments in Mk-801 induced schizophrenia rats by reducing the expression of NMDAR1 and MGLUR3, decreasing hippocampal tau hyperphosphorylation and inhibiting apoptosis through Akt /GSK-3β signaling pathway. Conclusions These findings suggest that combination therapy for enhancing NMDA receptors may be able to rescue cognition deficit in schizophrenia. More studies are needed to better elucidate these mechanisms.

Olanzapine Reverses MK-801-Induced Cognitive Deficits and Region-Specific Alterations of NMDA Receptor Subunits.

Glutamate Receptor 1 Phosphorylation at Serine 845 Contributes to the Therapeutic Effect of Olanzapine on Schizophrenia-Like Cognitive Impairments.

Psychotomimetic Effects of Different Doses of MK-801 and the Underlying Mechanisms in a Selective Memory Impairment Model

Olanzapine Attenuates the Okadaic Acid-Induced Spatial Memory Impairment and Hippocampal Cell Death in Rats

Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action

Differential Effects of Haloperidol, Clozapine and Olanzapine on Learning and Memory Functions in Mice

NMDA Receptor Hypofunction Induces Dysfunctions of Energy Metabolism and Semaphorin Signaling in Rats: a Synaptic Proteome Study.

The Effects of Low-Dose MK-801 Treatment on Reference Memory,spatial Working Memory and Reversal Learning in Rats.

Protective Effects of Shi-Zhen-An-Shen Decoction on the Cognitive Impairment in MK801-Induced Schizophrenia Model

Spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446/ST101) Treatment Rescues Olfactory Bulbectomy-Induced Memory Impairment by Activating Ca2+/Calmodulin Kinase II and Protein Kinase C in Mouse Hippocampus

Effects of olanzapine on the hypoglutamatergic schizophrenia model in mice

Persisting cognitive deficits induced by low-dose, subchronic treatment with MK-801 in adolescent rats

A Randomized Controlled Trial of Olanzapine Improving Memory Deficits in Han Chinese Patients with First-Episode Schizophrenia.

Metabolomic Analysis Reveals Metabolic Disturbance in the Cortex and Hippocampus of Subchronic Mk-801 Treated Rats

Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior]

Neurochemical Mechanisms of a Novel Alzheimer′s Disease Therapeutics on Improvement of Cognition and Depressive Behavior

Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity

Olanzapine Ameliorates Neuropathological Changes and Increases IGF-1 Expression in Frontal Cortex of C57BL/6 Mice Exposed to Cuprizone.

MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol

Chemogenetic attenuation of PFC pyramidal neurons restores deficits in recognition memory following adolescent NMDA receptor blockade

Repeated Blockade of NMDA Receptors During Adolescence Impairs Reversal Learning and Disrupts GABAergic Interneurons in Rat Medial Prefrontal Cortex